RLMD

Relmada is a clinical-stage biotech with no commercial products and effectively no revenue (FY trace amount of ~$5.1K is XBRL noise from a prior period, not operating sales). Management explicitly states 'We have not generated revenues and do not anticipate generating revenues for the foreseeable future,' so the headline P/S of 135,177x is meaningless — this is a binary asset-value story, not a fundamentals story. The cornerstone program esmethadone (REL-1017) for MDD was terminated after the Reliance II Phase 3 interim analysis came back futile, gutting the prior thesis. The company has pivoted to two early/mid-stage assets acquired in Q1 2025: sepranolone (Phase 2b-ready, from Asarina) for PWS/Tourette's, and NDV-01 (in-licensed from Trigone) for NMIBC bladder cancer — both years from any approval and unproven in pivotal trials.

The balance sheet is the most alarming line in the file. FY2025 cash & equivalents are just $3.50M against a $45.8M operating cash burn — roughly one month of runway at current spend. Even with $94M in current assets (likely including marketable securities raised during the recapitalization that drove a 216% increase in share count), the company has already diluted shareholders 3x in a single year and will need to raise again. The accumulated deficit is -$698M, equity is propped up only by the recent capital raise (+143.5% YoY to $86.5M), and R&D spend collapsed 41.8% as the Reliance II program wound down — a cost cut, not a productivity gain. G&A actually grew compensation expense by $7M even as the science was failing, which is a governance yellow flag.